News | March 21, 2024
Bristol Myers Squibb completes acquisition of Karuna Therapeutics
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
This partnership marks a significant step for the Company towards establishing renewable energy power generation using hybrid open excess through solar and wind sources
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
It is the first autotaxin inhibitor to be investigated in cancer patients
Vision loss due to Glaucoma can be prevented if it is detected and treated early
The validations confirm the completion of the applications and commence the scientific review process
The facility will manufacture Specialty and Fine Chemicals tailored to various applications across industries such as Polymer and Water Treatment facilities
Subscribe To Our Newsletter & Stay Updated
